All In Biotech

Drug Trial Radar · NCT05399030

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-332 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Aug 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Aug 14, 2021

Primary completion

Jan 30, 2022

Study completion Feb 18, 2022

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel group, single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-332 in Healthy Subjects

Conditions

  • Healthy Subjects

Interventions

  • ICP-332Drug

    ICP-332 will be administered as tablet

  • PlaceboOther

    Matching placebo will be administered as tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Treatment-Emergent Adverse Events (AEs).Time frame: Baseline up to 28 days after last dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jinan Central Hospital

    Jinan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.